This is an adaptive, multicenter, randomized, open-label, controlled trial to evaluate
the effectiveness and safety of quinine sulfate in mild to moderate COVID-19 hospitalized
adults with confirmed positive Rapid Test or PCR.

The study is a multi-center trial that will be conducted in up to approximately 2 sites
nationally. New sites may be added as needed after appropriate assessment. Interim
monitoring will be conducted to evaluate the arms and for effectiveness and safety. Any
change would be accompanied by an updated sample size.

Eligible patients are male and female patients aged ≥ 18 years to < 60 years old who are
hospitalized with Covid-19 based on clinical symptoms determined by physician and
confirmed by Rapid Test or PCR test with mild to moderate symptoms that fulfill the
inclusion and exclusion criteria stated in the protocol. Total Subjects: 100

Subjects with any of these conditions will be excluded:

- Received quinine sulfate, hydroxychloroquine, chloroquine, lumefantrine, or
mefloquine within 30 days prior to this research;

- Having receive any treatment for COVID-19 prior to this research;

- Any contraindication to quinine sulfate

- Inability to swallow pills or any other reason that compliance with the medical
regimen is not likely;

- Pregnant and breastfeeding;

- Severe underlying disease where treatment and follow up is not likely to be
beneficial to the patient based on physician judgement (e.g. retinopathy,
cardiovascular disease (QTc > 500 mdet (narrow QRS); QTc ≥ 550 mdet (wide QRS)),
heart arrythmia, uncontrolled diabetes mellitus, hypertension, chronic pulmonary
disease, asthma, chronic kidney disease (Creatinine > 2x normal value), liver
disease (SGOT/SGPT > 2x normal value), chronic neurological disease, or etc.). This
includes people requiring care in designated supported living facilities and severe
dementia;

- Platelet count less than 150,000 and more than 450,000 cells/μL;

- Possibility of being transferred to a non-study-hospital within 72 hours.

Any suspected serious adverse event reaction is reported to CRO/Sponsor and EC within 24
hours, using patient's study ID.

During the study conduct, the study team shall keep all the relevant source documents and
transcribe the data in case report form (CRF). The study team should also update study
essential document (e.g. subject log, investigational product accountability log, etc.)
and keep the copy captured by scan/camera for monitoring/audit/inspection purpose.

The study is expected to be finished in 1,5 years.

Standard of Care (SoC) treatment is based on COVID-19 Treatment Protocol (4th edition,
2020) published by Medical Associations (PDPI, PERKI, PAPDI,PERDATIN, IDAI).

MILD CASE:

Arm 1 = SoC alone Arm 2 = SoC + Quinine Sulfate (2 tablets of Quinine Sulfate 200 mg
administered orally once daily for 5 days).

MODERATE CASE:

Arm 1 = SoC alone Arm 2 = SoC + Quinine Sulfate (2 tablets of Quinine Sulfate 200 mg
administered orally every 12 hours in Day 1, followed with 2 tablets of Quinine Sulfate
200 mg administered once daily for 5-7 days).

It is anticipated that patients with COVID-19 will present to participating hospitals,
and that no external recruitment efforts towards potential subjects are needed.
Recruitment efforts may also include dissemination of information about this trial to
other medical professionals/hospitals.

The Ethics Committee will approve the recruitment process and all materials prior to any
recruitment to prospective subjects directly.

Screening will begin with a brief discussion with study staff. Some will be excluded
based on demographic data and medical history (i.e., pregnant, < 18 years of age, renal
failure, etc.). Information about the study will be presented to potential subjects (or
legally authorized representative) and questions will be asked to determine potential
eligibility. Screening procedures can begin only after informed consent is obtained.

To evaluate the effectiveness of Quinine Sulfate in the therapy of mild to moderate
hospitalized adults with confirmed COVID-19 based on subject's clinical condition
assessed using a 7-point ordinal scale. Secondary parameters will be Incidence and
duration of Oxygenation (days of oxygenation), incidence is defined as number of days
from randomization until the subject received oxygenation, duration is defined as total
days of the use of oxygenation; incidence of Ventilation (days to receiving ventilation)
and length of stay in hospital (after subject received randomization code until subject
discharge/death/recovered).

To evaluate the safety of quinine sulfate on laboratory parameters, serious adverse
events and QT interval based on ECG result.

- Change in CBC, SGOT, SGPT, Ureum and Creatinine;

- Number of reported Serious Adverse Event (SAE);

- Change in QT interval based on ECG result.

Analyses relate outcome to the randomly allocated treatment (e.g. intent-to-treat). The
primary analyses assess any effects of treatment allocation on all-cause in-hospital
mortality, analyzing separately people who already at mild and moderate level at entry
and those who did not. Interim analysis will be carried out after 50% subject enrolled. A
Data Safety Monitoring Board (DSMB) will monitor ongoing results to ensure subject
well-being and safety as well as study integrity. The DSMB will evaluate the study safety
parameter after 50% subject enrolled in the study.

The main secondary analyses assess any effects of treatment allocation on:

- Duration of hospitalization (time from randomization to discharge) (days);

- Incidence and duration of Oxygenation;

- Incidence and duration of Ventilation;

- Clinical outcome from baseline at day 10 or if discharged earlier

Study related data will be recorded in electronically. All the data in the source
documents shall be collected by the study team to be transcribed in the electronic case
report form (eCRF) and other study documents are stored in the electronic trial master
file (eTMF). Once the document recorded, the electronic data will be automatically
available for monitoring/audit/inspection purpose. All the electronic system used and
data recording in the study must be conducted in compliance to Good Clinical Practice.

The investigator must assure that subjects' anonymity will be maintained and that their
identities are protected from unauthorized parties. On CRFs or other documents submitted
to the funder, subjects should not be identified by their names, but by an identification
code. The investigator should keep a subject enrolment log showing codes, names and
addresses. The investigator should maintain documents not for submission to funder, e.g.
subjects' written consent forms, in strict confidence.

The investigator shall ensure the quality control and quality assurance of the data
generated during the study and how the data will be handled, including providing access
to monitoring activities, audit and inspection and source documents which will be used in
the study. Investigator will permit monitoring, audits and inspections by funder/CRO, EC,
and regulatory bodies.

All source records including electronic data (if any) will be stored in secured systems
in accordance with institutional policies and locally applicable regulation. All the
essential documents should be retained until at least 5 years after the study ended or
based on the applicable regulatory requirements or based on the agreement with the
funder.

The Drug Safety Monitoring Board (DSMB) is an Independent Data Monitoring Committee
consisting of doctors who are experienced in clinical trials, statisticians, and other
members who do not direct involvement with this study. The DSMB responsible for the
ongoing review of a clinical trial and for making recommendations to the sponsor
concerning the continuation, modification, and termination of the trial as it is being
conducted. The DSMB will be the only committee that is allowed to review the confidential
data in the study. The statistician will analyze the subject's security data and report
to DSMB to be evaluated more closely. The key responsibilities of the DSMB are to ensure
patient safety by routine review of overall safety data including all SAEs, SUSARs, all
severe AEs and AEs leading to drug or study discontinuation and, where applicable,
literature cases and information from Competent Authorities(CAs) and by judging the
relevance of the events for patients' safety. The DSMB will review the results of data
that has been analyzed in accordance with SAP and consider other evidence arising from
other studies and will provide advice to the Trial Steering Committee (TSC) (the research
committee and national coordinator) regarding the sustainability of this study. The DSMB
may recommend the TSC to the recruitment or study termination or provide recommendations
related to alternatives treatment (if any)